Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months

5/20/24 8:31:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $EOLS alert in real time by email

Get the next $EOLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EOLS

Date	Price Target	Rating	Analyst
1/29/2024	$10.00 → $16.00	Equal Weight → Overweight	Barclays
6/23/2022	$18.00	Buy	Needham
5/12/2022	$8.00 → $10.00	Underweight → Equal Weight	Barclays
1/20/2022	$11.00	Hold → Buy	Truist
11/3/2021	$22.00 → $15.00	Buy	HC Wainwright & Co.

More analyst ratings

Evolus Announces Appointment of Albert G. White III to Board of Directors
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
7/1/24 8:00:00 AM ET
$COO
$EOLS
Ophthalmic Goods
Health Care
Biotechnology: Pharmaceutical Preparations
Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati
1/4/24 4:05:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:
8/21/23 8:45:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

$EOLS
Financials

Live finance-specific insights

Evolus Reports Third Quarter 2024 Results
Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and Launch Expected by September 2025 Narrows Full-Year 2024 Net Revenue Guidance to $260 Million to $266 Million, Representing Year-Over-Year Growth of 29% to 32% Reaffirms Non-GAAP Profitability1 in Q4 2024 and Full Year 2025
11/6/24 4:05:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus to Report Third Quarter Financial Results on November 6, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic r
10/23/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus to Report Second Quarter Financial Results on July 31, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic
7/17/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

$EOLS
Press Releases

Fastest customizable press release news feed in the world

Evolus Reports Third Quarter 2024 Results
Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and Launch Expected by September 2025 Narrows Full-Year 2024 Net Revenue Guidance to $260 Million to $266 Million, Representing Year-Over-Year Growth of 29% to 32% Reaffirms Non-GAAP Profitability1 in Q4 2024 and Full Year 2025
11/6/24 4:05:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus to Participate in Stifel 2024 Healthcare Conference
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. O
11/1/24 8:00:00 AM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced "esteem"), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion1. The CE Mark certification, through the new MDR process represents more stringent requirements, designed to ensure the safety, efficacy, and quality of
10/31/24 2:02:00 PM ET
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care

Evolus Dermal Filler Evolysse Lift Meets Primary Endpoint, Demonstrates Superiority To Restylane-L At 6 Months; Shows Statistically Significant Improvement In Nasolabial Fold Severity Compared To Restylane-L At All Timepoints Over 12 Months

Chat with this insight

Recent Analyst Ratings for $EOLS

$EOLS SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Evolus Inc.

SEC Form S-8 filed by Evolus Inc.

SEC Form 10-Q filed by Evolus Inc.

$EOLS Leadership Updates

Live Leadership Updates

$EOLS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Evolus Announces Appointment of Albert G. White III to Board of Directors

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

Chief Financial Officer Beaver Sandra sold $49,074 worth of shares (3,276 units at $14.98), decreasing direct ownership by 2% to 148,502 units (SEC Form 4)

Chief Marketing Officer Yamagishi-Dressler Tomoko sold $89,251 worth of shares (5,631 units at $15.85), decreasing direct ownership by 6% to 82,375 units (SEC Form 4)

Director White Albert G Iii was granted 23,014 shares (SEC Form 4)

$EOLS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Evolus Inc.

Amendment: SEC Form SC 13G/A filed by Evolus Inc.

Amendment: SEC Form SC 13G/A filed by Evolus Inc.

$EOLS Financials

Live finance-specific insights

Evolus Reports Third Quarter 2024 Results

Evolus to Report Third Quarter Financial Results on November 6, 2024

Evolus to Report Second Quarter Financial Results on July 31, 2024

$EOLS Press Releases

Fastest customizable press release news feed in the world

Evolus Reports Third Quarter 2024 Results

Evolus to Participate in Stifel 2024 Healthcare Conference

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

$EOLS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$EOLS Market Insights

Live Market Insights

Evolus upgraded by Barclays with a new price target

Needham initiated coverage on Evolus with a new price target

Evolus upgraded by Barclays with a new price target

Evolus Announces Submission Of Premarket Approval Application To The U.S. FDA For First Two Evolysse Dermal Filler Products

Cantor Fitzgerald Reiterates Overweight on Evolus

Evolus Expands International Presence With Launch Of Nuceiva In Spain

Recent Analyst Ratings for
$EOLS

$EOLS
SEC Filings

$EOLS
Leadership Updates

$EOLS
Insider Trading

$EOLS
Large Ownership Changes

$EOLS
Financials

$EOLS
Press Releases

$EOLS
Analyst Ratings

$EOLS
Market Insights